SCR-LIP-000636 · Claim · machine-readable JSON →

Systemic inflammatory markers are inconsistently elevated in lipedema.

General proposition consolidated from 4 earlier single-paper claims; each study's own result is shown as its finding.

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
very low (GRADE)
Evidence
4 source(s)
Dates
2026-11-20 → 2026-11-20

Structured evidence, machine-compiled — not a verdict.

Evidence over time

20202026Adipose Tissue Hypertrophy, An Aberrant Biochemical Profile and Distinct Gene Expression in Lipedema — Felmerer et al. (2020) · conflictingLipedema Research—Quo Vadis? — Ernst et al. (2023) · consistentThe Molecular Mechanisms Underlying Dercum’s Disease: Exploring the Intersection of Obesity, Pain, and Inflammation — Reytor-González et al. (2025) · consistentInflammatory Markers in Lipedema: A Comparative Analysis of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Mean Platelet Volume (2026) · consistent

Evidence (4)

Context (PECO)

Populationpatients with lipedema vs controls
Conditionlipedema
Exposurelipedema diagnosis
Comparatorcontrols without lipedema
Outcomehematological inflammatory markers (NLR, PLR, MPV, PDW, CRP)
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Change log